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changes in MRL on payer’s and patient’s one year budget on the
example of angiotensin II blockers. METHODS: The three
models were build to assess the changes in payer’s and patient’s
budget/per patient if therapy is conducted using: 1) the only
original medications;2) only generic medications; or 3) if therapy
had been started with original medications and changed to the
generic (after changes on the list). All costs in polish zloty (zł): 1
euro ~ 3.80 zl. RESULTS: In all models (from 1 to 3) the payer’s
payment will decrease from 281 zł to 154 zł pe patient. From the
patient’s perspective the one year payment will rise from 767 zł
to 1048 zł or from 449 zł to 577 zł—depends on medication (in
model 1) and from 281 zł to 409 zł (in model 2), only in model
3 it will decrease from 767 zł to 409 zł. CONCLUSION: The
changes in MRL may lead to reduction of payer’s expenditures
and usually increase the patient’s expenditures. As a result it
could leads to reduction in patient’s access to medications.
PCV16
HEALTH INSURANCE COSTS OF STROKE HOSPITAL
TREATMENTS IN HUNGARY; 2003–2005
Karpati K1, Boncz I2, Lindgren P3, Ekman M4, Brodszky V1, Majer I1,
Bereczki D5, Gulácsi L1
1Corvinus University of Budapest, Budapest, Hungary, 2National
Health Insurance Fund Administration, Budapest, Hungary, 3i3/innovus,
Stockholm, Sweden, 4Stockholm Health Economics, Stockholm,
Sweden, 5University of Debrecen, Debrecen, Hungary
OBJECTIVES:Our aimwas to assess the social insurance costs of
hospital treatments for acute stroke inHungary between 2003 and
2005.We studied howmuch burden stroke patients impose on the
ﬁnancer (National Health Insurer Fund Administration) in acute
and chronic hospital admissions. METHODS: We extracted the
data of ‘new’ stroke patients (ICD-10: I60–64 diagnosis) hospi-
talized in May 2003 from the database of the ﬁnancer. We
analyzed active and chronic hospital treatment costs of these
patients in the period of 12 months before the stroke and in the
following ﬁrst and second 12 months. Data were distributed by
sex and age (age groups: 25–44, 45–64, over 65). We studied
patients hospitalized in May 2003 with the ICD-10: I60–64 main
diagnosis but not treated with the same diagnosis in the previous
24 months.RESULTS: In the ﬁrst 12 months of the active care the
burden of the disease was (male vs. female) 65+: 1018.4 vs. 823.2;
45–64: 1365.6 vs. 1122.0; 25–44: 1480.4 vs. 1224.4 Euro per
patient. In the second 12 months the costs were 202.4 vs. 144.8;
96.8 vs. 130.4; 110.4 vs. 99.2 Euro respectively.CONCLUSION:
Annual stroke costs of the Insurance Fund—based on our inci-
dence data (3535 patients/month)—amounted to 37.6 million
Euros in active and to 4.3 million Euros in chronic hospital care in
the ﬁrst 12 months, which is 1.68% of the total budget. Average
costs of stroke are higher in the case of males as are in the case of
females, 1459.2 vs. 1212.0 Euro in the ﬁrst 24 months. The
signiﬁcant difference results from active hospital treatment costs
(1326.0 vs. 1048.4 Euro), while the discrepancy is smaller in the
chronic hospital care (133.2 vs. 163.6 Euro).
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OBJECTIVES: Estimate the budget impact and the level of thera-
peutic goal attainment among patients with high cardiovascular
risk (HCR) in a population attending primary care setting (PCS)
and Hospital centres (HC) in a Spanish area. METHODS: Obser-
vational multicentre longitudinal study. Patients >55 years old
from seven PCC and two HC were recruited during 2006.
Deﬁnition of HCR as per modiﬁed NCEP-ATP III criteria.
The control cohort: patients without HCR. Main measures:
cardiovascular/general comorbidities, Charlson score (severity
[iCh]), clinical parameters (DP, SP, glucose, cholesterol, HCLc,
LDLc) and total costs variable/semi ﬁxed (visits, tests, drugs,
admissions, derivations, emergencies etc). A logistic regression
and covariance model was developed (ANCOVA-Bonferroni) to
correct the models (comorbidities-cost). SPSS program was used.
Level of signiﬁcance was p < 0.05. RESULTS: In all, 24,410
patient were studied, 15.4% (n = 2.766; IC:14,9–15,9%;
p = 0,000) had HCR, mean age: 68,2  9,5 years, women:
55,2%. HCR was associated with: men (OR = 2,7; IC:2,5–3,0),
dyslipidemia (OR = 1,5; IC:1,4–1,6), hypertension (OR = 1,2;
IC:1,1–1,3), diabetes (OR = 1,1; IC:1,0–1,2) and iCh (OR = 2,1;
IC:1,9–2,2), p < 0,0001. Differences for the group with and
without HCR were: Metabolic control: DP: 77,5  9,5 vs.
74,8  9,7; glucose: 104,0  29,4 vs. 111,3  36,5; Total cho-
lesterol: 211,6  38,7 vs. 192,4  41,5; LDL-cholesterol:
128,7  35,4 vs. 112,5  36,0; p = 0,000. HCR was related to
poly-pharmacy (62,5% vs. 26,1%) and average number of drugs
(6,4  3,5 for the HCR group vs. 4,0  2,9), p < 0,001. Drugs
accounted for 43.4% of total costs. Unitary adjusted cost per
year was 2.445.98€ (IC:2.382,07–2.509,90) for the HCR group
vs. 1.537,33€ (IC:1.505,53–1.569,13), p < 0.001. All compo-
nents of costs showed signiﬁcant differences between groups.
CONCLUSION: Patients with HCR had higher rates of
co-morbidity. Achievement of therapeutic objectives should
improve in patients without hypertension and total cholesterol
but with HCR (glucose, cLDL). Patients with this proﬁle use
more resources (particularly more drugs) and have higher health
care costs. Health professionals should develop common strate-
gies oriented to control main cardiovascular risk factors in
primary care.
PCV18
ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF
EXPLANTED ORGANS IN HEARTTRANSPLANTATION
Kalo Z
Szeged University, Szeged, Hungary
OBJECTIVES: Surgical techniques and immunosuppressive
drugs have been improved over the past decades, while the
method of preserving and transporting organs has not. In the UK
only 22.3% of hearts from all consented heart beating donors
were recovered in June 2005, whilst cold ischeamic time (CIT)
increased by an average of 34 minutes over 8 years. The Organ
Care System (OCS) may alleviate the organ shortage and
improve transplant outcomes by maintaining explanted hearts in
the normal functioning state ex-vivo. A health economic evalu-
ation analysis was undertaken to compute the economic beneﬁt
of improved transportability of explanted hearts from the UK
societal point of view. METHODS: Improved preservation with
OCS plus heart transplantation (IPTx) was compared to medical
management on the transplantation waiting list (MM) and heart
transplantation with conventional cold preservation method
(CPTx). We assumed that IPTx increases heart transplantation
rates by 40% and reduces CIT to <1 hr. UK cost vectors were
derived from the published literature. Twenty year direct medical
costs and QALYs were calculated for each arm. Reducing CIT to
<1 hr may extend the graft half life by 2.2 years (Schnitzler
2006). Discount rates of 6% were used for costs and 1.5% for
QALYs. WTP for a QALY gain was assumed to be 30,000 British
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